Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer

Satomi Tanaka, Junji Uchino, Takashi Yokoi, Takashi Kijima, Yasuhiro Goto, Yoshifumi Suga, Yuki Katayama, Ryota Nakamura, Kenji Morimoto, Akira Nakao, Makoto Hibino, Nozomi Tani, Takayuki Takeda, Hiroyuki Yamaguchi, Yusuke Tachibana, Chieko Takumi, Noriya Hiraoka, Masafumi Takeshita, Keisuke Onoi, Yusuke ChiharaRyusuke Taniguchi, Takahiro Yamada, Yohei Matsui, Osamu Hiranuma, Yoshie Morimoto, Masahiro Iwasaku, Shinsaku Tokuda, Yoshiko Kaneko, Tadaaki Yamada, Koichi Takayama

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Combination therapy with immune checkpoint inhibitors and cytotoxic chemotherapies (chemoimmunotherapy) is associated with significantly better survival outcomes than cytotoxic chemotherapies alone in patients with advanced non-small cell lung cancer (NSCLC). However, there are no prognostic markers for chemoimmunotherapy. The prognostic nutritional index (PNI) and lung immune prognostic index (LIPI) are prognostic biomarkers for immune checkpoint.

Original languageEnglish
Article number423
JournalDiagnostics
Volume12
Issue number2
DOIs
Publication statusPublished - 02-2022

All Science Journal Classification (ASJC) codes

  • Clinical Biochemistry

Fingerprint

Dive into the research topics of 'Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer'. Together they form a unique fingerprint.

Cite this